MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from issuance ofshares of common stock...$15,573,966 Proceeds from issuance ofshares of common stock...$4,592,462 Proceeds from issuance ofshares of common stock...$3,826,336 Proceeds from theexercise of stock options$34,115 Net cash provided byfinancing activities$23,724,054 Canceled cashflow$302,825 Net change in cashand cash...$4,517,801 Canceled cashflow$19,206,253 Deferred offering costs$302,825 Stock-based compensationexpense$6,046,661 Other assets-$110,548 Prepaid assets and othercurrent assets-$82,282 Interest accrued onlicense payable$20,250 Net cash used inoperating activities-$19,206,253 Canceled cashflow$6,259,741 Net loss-$22,227,852 Other accruedexpenses-$2,354,504 Accounts payable-$512,536 Accrued compensation-$300,145 Accrued interest-$70,957
Cash Flow
source: myfinsight.com

ACTUATE THERAPEUTICS, INC. (ACTU)

ACTUATE THERAPEUTICS, INC. (ACTU)